FDA Warning Letter · #711330
Chengdu Brilliant Biopharmaceutical Co., Ltd. — FDA Warning Letter (September 11, 2025)
In plain English
Manufacturing practicesFDA cited Chengdu Brilliant Biopharmaceutical Co., Ltd. for not following current good manufacturing practice (CGMP), the federal quality rules for making drugs. The letter involves semaglutide.
What it means for you
This letter is about manufacturing quality at the time of FDA’s review. If this company makes or fills your medication, ask your provider whether the problems have been fixed, and don’t stop a prescribed medicine without talking to your prescriber.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025
Letter details
- Company
- Chengdu Brilliant Biopharmaceutical Co., Ltd.
- Letter number
- #711330
- Issue date
- September 11, 2025
- Subject
- CGMP/Finished Pharmaceuticals/Adulterated
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
What this letter means if you use compounded GLP-1s
A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Chengdu Brilliant Biopharmaceutical Co., Ltd. to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.
How a drug is made is the part of compounding a patient cannot inspect. What PCAB accreditation does and does not tell you and our review of impurities in compounded GLP-1s explain how quality is checked; the semaglutide page covers the approved versions.
Other warning letters in our database
- Motionpharmacycom — September 10, 2025
- Try Nova MD — September 9, 2025
- SemaBio — September 9, 2025
- Novo Nordisk Inc. — September 9, 2025
- Medclub Dr Jenn — September 9, 2025
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory